Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases

Basit Öğe Kaydı
dc.authoridDoğan, İzzet/0000-0003-1018-1119
dc.authoridkahraman, seda/0000-0002-5328-6554
dc.authoridPaksoy, Nail/0000-0003-4636-2595
dc.authoridSahin, Elif/0000-0002-1976-3951
dc.authorwosidDoğan, İzzet/AAB-6635-2020
dc.authorwosidkahraman, seda/KHU-2244-2024
dc.authorwosidPaksoy, Nail/HKF-3015-2023
dc.contributor.authorKahraman, Seda
dc.contributor.authorKarakaya, Serdar
dc.contributor.authorKaplan, Muhammed Ali
dc.contributor.authorGoksu, Sema Sezgin
dc.contributor.authorOzturk, Akin
dc.contributor.authorIsleyen, Zehra Sucuoglu
dc.contributor.authorHamdard, Jamshid
dc.date.accessioned2024-05-19T14:46:06Z
dc.date.available2024-05-19T14:46:06Z
dc.date.issued2024
dc.departmentİstinye Üniversitesien_US
dc.description.abstractCentral nervous system (CNS) metastases can be seen at a rate of 30% in advanced stages for patients with non-small cell lung cancer (NSCLC). Growing evidence indicates the predictive roles of driver gene mutations in the development of brain metastases (BM) in recent years, meaning that oncogene-driven NSCLC have a high incidence of BM at diagnosis. Today, 3rd generation targeted drugs with high intracranial efficacy, which can cross the blood-brain barrier, have made a positive contribution to survival for these patients with an increased propensity to BM. It is important to update the clinical and pathological factors reflected in the survival with real-life data. A multi-center, retrospective database of 306 patients diagnosed with driver mutant NSCLC and initially presented with BM between between November 2008 and September 2022 were analyzed. The median progression-free survival (mPFS) was 12.25 months (95% CI, 10-14.5). While 254 of the patients received tyrosine kinase inhibitor (TKI), 51 patients received chemotherapy as first line treatment. The median intracranial PFS (iPFS) was 18.5 months (95% CI, 14.8-22.2). The median overall survival (OS) was 29 months (95% CI, 25.2-33.0). It was found that having 3 or less BM and absence of extracranial metastases were significantly associated with better mOS and iPFS. The relationship between the size of BM and survival was found to be non-significant. Among patients with advanced NSCLC with de novo BM carrying a driver mutation, long-term progression-free and overall survival can be achieved with the advent of targeted agents with high CNS efficacy with more conservative and localized radiotherapy modalities.en_US
dc.identifier.doi10.1038/s41598-024-56046-w
dc.identifier.issn2045-2322
dc.identifier.issue1en_US
dc.identifier.pmid38461209en_US
dc.identifier.scopus2-s2.0-85187188671en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org10.1038/s41598-024-56046-w
dc.identifier.urihttps://hdl.handle.net/20.500.12713/5441
dc.identifier.volume14en_US
dc.identifier.wosWOS:001185505600041en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherNature Portfolioen_US
dc.relation.ispartofScientific Reportsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240519_kaen_US
dc.subjectOncogene-Driven Advanced Non-Small Cell Lung Canceren_US
dc.subjectDe Novo Brain Metastasesen_US
dc.subjectSurvival Related Parametersen_US
dc.titleTreatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastasesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu